TokenPost·
Eloxx Pharmaceuticals Posts $0.49 Q3 GAAP Loss Per Share, Beats Estimate

$56.3M
cash on hand
Cash and cash equivalents were $56.3 million on Sept. 30, down from $62 million on June 30. The company said it believes its cash can fund operations into 2028.